{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '10.1.7', 'Visit 7 (Week 10 [+ 3 days])', '86', '10.1.8', 'Visit 8 (Week 12 [+ 3 days])', '87', '10.1.9 Visits 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 (Weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, 50) -', 'IMP Administration at Patient Home or Investigative Site', '89', '10.1.10', 'Visits 10, 12, 16, 18, 22, 24, 26 (Weeks 16, 20, 28, 32, 40, 44, 48)', '89', '10.1.11', 'Visit 14 (Week 24 [+ 3 days])', '91', '10.1.12', 'Visit 20 (Week 36 [+ 3 days])', '92', '10.1.13 Visit 28 (Week 52 [+ 3 days], End of Treatment, and Early Treatment Discontinuation)', '94', '10.1.14 Visit 29 and Visit 30 (Weeks 56 and 60 5 days), Post-Treatment Period)', '95', '10.1.15', 'Visit 31 (Week 64, End of Study Visit)', '96', '10.2', 'DEFINITION OF SOURCE DATA', '97', '10.3', 'HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT', 'DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION', '97', '10.3.1', 'Temporary Treatment Discontinuation With Investigational Medicinal Product(s)', '98', '10.3.2', 'Permanent Treatment Discontinuation With Investigational Medicinal Product(s)', '98', '10.3.3', 'List of Criteria for Permanent Treatment Discontinuation', '98', '10.3.4', 'Handling of Patients After Permanent Treatment Discontinuation', '99', '10.3.5', 'Procedure and Consequence for Patient Withdrawal From Study', '100', '10.4', 'OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING', '100', '10.4.1', 'Definitions of Adverse Events', '100', '10.4.1.1', 'Adverse Event', '100', '10.4.1.2', 'Serious Adverse Event', '101', '10.4.1.3 Adverse Event of Special Interest', '102', '10.4.2', 'Serious Adverse Events Waived From Expedited Regulatory Reporting to Regulatory', 'Authorities', '103', '10.4.3', 'General Guidelines for Reporting Adverse Events', '103', '10.4.4', 'Instructions for Reporting Serious Adverse Events', '104', '10.4.5', 'Guidelines for Reporting Adverse Events of Special Interest', '105', '10.4.6', 'Guidelines for Management of Specific Laboratory Abnormalities', '105', '10.5', 'OBLIGATIONS OF THE SPONSOR', '105', '10.6', 'SAFETY INSTRUCTIONS', '106', '10.6.1', 'Hypersensitivity', '106', '10.6.2', 'Severe Injection Site Reactions', '106', '10.6.3', 'Infections', '107', '10.6.4', 'Elevated Liver Function Tests', '108', '10.7', 'ADVERSE EVENTS MONITORING', '108', 'Property of the Sanofi Group - strictly confidential', 'Page 29', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '11', 'STATISTICAL CONSIDERATIONS', '109', '11.1', 'DETERMINATION OF SAMPLE SIZE', '109', '11.2', 'DISPOSITION OF PATIENTS', '110', '11.3', 'ANALYSIS POPULATIONS', '110', '11.3.1', 'Efficacy Populations', '110', '11.3.2', 'Safety Population', '111', '11.3.3', 'Systemic Drug Concentration Population', '111', '11.3.4', 'Anti-drug Antibody (ADA) Population', '111', '11.4', 'STATISTICAL METHODS', '112', '11.4.1', 'Extent of Study Treatment Exposure and Compliance', '112', '11.4.1.1 Extent of Investigational Medicinal Product Exposure', '112', '11.4.1.2', 'Compliance', '112', '11.4.2', 'Analyses of Efficacy Endpoints', '112', '11.4.2.1', 'Analysis of Primary Efficacy Endpoint(s)', '113', '11.4.2.2 Analyses of Secondary Efficacy Endpoints', '114', '11.4.2.3', 'Multiplicity Considerations', '116', '11.4.2.4 Handling of Missing Data', '117', '11.4.3', 'Analyses of Safety Data', '117', '11.4.3.1', 'Adverse Events', '118', '11.4.3.2 Clinical Laboratory Evaluation, Vital Signs and Electrocardiogram Data', '119', '11.4.3.3 Humoral Immune Response to Vaccines', '119', '11.4.4', 'Analyses of Systemic Drug Concentration, Anti-drug Antibodies, and Pharmacodynamic', 'Variables', '120', '11.4.4.1 Drug Concentration Analysis', '120', '11.4.4.2', 'Anti-drug Antibodies Analysis', '120', '11.4.4.3 Pharmacodynamics and Phenotyping', '121', '11.4.5', 'Analyses of Patient Reported Outcomes (Health-related Quality of Life/Health Economics', 'Variables)', '121', '11.5', 'INTERIM ANALYSIS', '121', '11.6', 'PLANNED DATABASE LOCK', '122', '12', 'ETHICAL AND REGULATORY CONSIDERATIONS', '123', '12.1', 'ETHICAL AND REGULATORY STANDARDS', '123', '12.2', 'INFORMED CONSENT', '123', '12.3', 'HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT', 'ETHICS COMMITTEE (IRB/IEC)', '124', '13', 'STUDY MONITORING', '126', 'Property of the Sanofi Group - strictly confidential', 'Page 30', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}